Association of LILRA3 gene variants with central nervous system demyelinating syndromes of autoimmune origin in patients with late disease onset
- 1Department of Physiology, School of Medicine, National and Kapodistrian University of Athens
- 2First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens
Abstract
Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) gene variants have been previously associated with multiple sclerosis (MS). This study aimed to explore the prevalence of LILRA3 gene variants in a Greek cohort of patients with CNS demyelinating disorders, including those with MS, Systemic Autoimmune Disease (SAD) with CNS involvement, and Demyelinating disease with Autoimmune Features (DAF). The latter describes a group of patients who present with MS-like manifestations, as well as features of systemic autoimmunity. We included 439 patients (344 MS, 27 SAD with CNS involvement, 68 DAF) and 381 healthy controls (HC) that were genotyped for LILRA3 gene variants. The LILRA3 +/− heterozygous deletion was significantly less frequent in MS patients compared to HCs (8.14% vs. 14.43%, p-value: 0.0086; OR [95% CI] 0.53 [0.33–0.85]). Of interest, in adult-onset MS (AOMS), the LILRA3 +/− genotype frequency was significantly lower than in their HC counterparts (7.53% vs. 15.69%, p = 0.0424, OR [95% CI] 0.44 [0.21–0.94]). When focusing on MS patients aged 50 or older (Late-onset MS, LOMS), no such differences were observed. Finally, the LILRA3 +/− heterozygous deletion was found to be significantly more prevalent in DAF patients compared to MS and HC groups of age distribution ≥ 50 years old (40.0% vs. 5.56% and vs. 14.03, p-values 0.03 and 0.016, respectively; ORs [95% CI] 11.3 [1.18–109.26] and 4.085 [1.38–12.12) respectively. In summary, these findings support that the type and age of onset of different demyelinating syndromes is shaped by distinct underlying genetic background.
Related
- Autoimmune diseases and autoimmune polyglandular syndromes in adult patients with biopsy-confirmed celiac disease: A prospective study.
- The role of the JAK/STAT pathway in the pathogenesis and treatment of post-COVID autoimmune syndromes
- Diagnostic Yield of Expanded Multigene Testing in Hereditary Polyposis Syndromes: Functional Characterization of Clinically Relevant Variants
- Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Japanese Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: A Phase 3, Open-label Clinical Trial
- 2026 Focused Update of the Saudi Heart Association Guidelines on Best Practices in the Management of Chronic Coronary Syndromes.
BibTeX
@article{raftopoulou2026association,
title = {{Association of LILRA3 gene variants with central nervous system demyelinating syndromes of autoimmune origin in patients with late disease onset}},
author = {Sylvia Raftopoulou and Vassilis E. Papadopoulos and Dimitris Karathanasis and Anna Rapti and Charalampos Skarlis and Maria-Eleftheria Evangelopoulos and Clio P. Mavragani},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-59125-2},
url = {https://doi.org/10.1038/s41598-026-59125-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Association of LILRA3 gene variants with central nervous system demyelinating syndromes of autoimmune origin in patients with late disease onset
AU - Sylvia Raftopoulou
AU - Vassilis E. Papadopoulos
AU - Dimitris Karathanasis
AU - Anna Rapti
AU - Charalampos Skarlis
AU - Maria-Eleftheria Evangelopoulos
AU - Clio P. Mavragani
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-59125-2
UR - https://doi.org/10.1038/s41598-026-59125-2
AB - Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) gene variants have been previously associated with multiple sclerosis (MS). This study aimed to explore the prevalence of LILRA3 gene variants in a Greek cohort of patients with CNS demyelinating disorders, including those with MS, Systemic Autoimmune Disease (SAD) with CNS involvement, and Demyelinating disease with Autoimmune Features (DAF). The latter describes a group of patients who present with MS-like manifestations, as well as features of systemic autoimmunity. We included 439 patients (344 MS, 27 SAD with CNS involvement, 68 DAF) and 381 healthy controls (HC) that were genotyped for LILRA3 gene variants. The LILRA3 +/− heterozygous deletion was significantly less frequent in MS patients compared to HCs (8.14% vs. 14.43%, p-value: 0.0086; OR [95% CI] 0.53 [0.33–0.85]). Of interest, in adult-onset MS (AOMS), the LILRA3 +/− genotype frequency was significantly lower than in their HC counterparts (7.53% vs. 15.69%, p = 0.0424, OR [95% CI] 0.44 [0.21–0.94]). When focusing on MS patients aged 50 or older (Late-onset MS, LOMS), no such differences were observed. Finally, the LILRA3 +/− heterozygous deletion was found to be significantly more prevalent in DAF patients compared to MS and HC groups of age distribution ≥ 50 years old (40.0% vs. 5.56% and vs. 14.03, p-values 0.03 and 0.016, respectively; ORs [95% CI] 11.3 [1.18–109.26] and 4.085 [1.38–12.12) respectively. In summary, these findings support that the type and age of onset of different demyelinating syndromes is shaped by distinct underlying genetic background.
SN - 2045-2322
ER -